SCHEMBL5482526

SCHEMBL5482526

OCC1CCCCCN1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31350235 1.00 CYP2D6 (0.52)
SCHEMBL31048379 1.00
Hydrochloric Acid SCHEMBL31323394 0.98 KMT2A (0.50)
SCHEMBL94571 0.97
SCHEMBL703052 0.97
SCHEMBL1872941 0.97
Hydrochloric Acid SCHEMBL2011967 0.95
Hydrochloric Acid SCHEMBL2011971 0.95
Bromide SCHEMBL11156909 0.95
Hydrochloric Acid SCHEMBL4328612 0.95

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-205907109-U Resourceful treatment system that contains ammonia nitrogen wastewater of urotropine methyl alcohol 呼图壁县锐源通化工有限责任公司 2017-01-25 CN claimed
US-6846827-B1 Pyrimidine derivatives ASTRAZENECA AB (SE) 2005-01-25 US claimed
EP-1226126-B1 PYRIMIDINE DERIVATIVES ASTRAZENECA AB (SE) 2005-01-05 EP claimed
EP-1226126-A1 PYRIMIDINE DERIVATIVES AstraZeneca AB (SE) 2002-07-31 EP claimed
WO-2001027089-A1 PYRIMIDINE DERIVATIVES ASTRAZENECA AB (SE) 2001-04-19 WO claimed
US-20250250287-A1 HETEROCYCLIC COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH BEIGENE SWITZERLAND GMBH (CH) 2025-08-07 US disclosed
EP-4568973-A1 HETEROCYCLIC COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH BeiGene Switzerland GmbH (CH) 2025-06-18 EP disclosed
EP-4565590-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF Kumquat Biosciences Inc. (US) 2025-06-11 EP disclosed
CN-119654327-A Heterocyclic compounds, compositions thereof and methods of treatment thereof 百济神州(苏州)生物科技有限公司 2025-03-18 CN disclosed
US-20240390389-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF KUMQUAT BIOSCIENCES INC. 2024-11-28 US disclosed
US-12059425-B2 Heterocyclic compounds and uses thereof KUMQUAT BIOSCIENCES INC. (US) 2024-08-13 US disclosed
US-20240226113-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF KUMQUAT BIOSCIENCES INC. 2024-07-11 US disclosed
US-6545038-B1 N-substituted 3-oxyaminocarbonyl-1,4-oxazonine or -thiazonine derivatives THE PROCTER & GAMBLE COMPANY 2003-04-08 US disclosed
EP-0925287-B1 HETEROCYCLIC METALLOPROTEASE INHIBITORS PROCTER & GAMBLE (US) 2003-01-15 EP disclosed
EP-1226126-A1 PYRIMIDINE DERIVATIVES AstraZeneca AB (SE) 2002-07-31 EP disclosed
WO-2001027089-A1 PYRIMIDINE DERIVATIVES ASTRAZENECA AB (SE) 2001-04-19 WO disclosed
US-6166005-A Heterocyclic metalloprotease inhibitors THE PROCTER & GAMBLE COMPANY 2000-12-26 US disclosed
EP-0925287-A1 HETEROCYCLIC METALLOPROTEASE INHIBITORS THE PROCTER & GAMBLE COMPANY (US) 1999-06-30 EP disclosed
WO-1998008827-A1 HETEROCYCLIC METALLOPROTEASE INHIBITORS THE PROCTER & GAMBLE COMPANY (US) 1998-03-05 WO disclosed
US-3998827-A HYPOTENSIVE AGENTS THE UPJOHN COMPANY (US) 1976-12-21 US disclosed